Sjögren’s Syndrome News

Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate significant improvement vs. those who receive placebo at week 24, according to data presented at the EULAR 2024 Congress.

Most pediatric patients with Sjögren’s disease displayed an interferon signature in their blood and parotid gland tissue, which could help confirm diagnoses and shorten treatment delays, according to data presented at EULAR 2024 Congress.

Sjögren’s disease is one of the most common autoimmune diseases but one of the least known, so to raise awareness of the condition, April is designated Sjögren’s Awareness Month.

This episode digs into the pathophysiology of urticaria vasculitis from anti-C1q to the story of bradykinin.

Patients with prior sinusitis demonstrate an increased risk for many rheumatic diseases, including antiphospholipid syndrome, Sjögren’s disease and seronegative rheumatoid arthritis, according to data published in RMD Open.

Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.

A phase 3 clinical trial of tivanisiran failed to meet the primary endpoint in the treatment of dry eye disease associated with Sjörgren’s syndrome, according to a press release from Sylentis.

Nipocalimab met the primary endpoint in a pivotal phase 3 trial in patients with generalized myasthenia gravis, as well as in a phase 2 study in adults with Sjögren’s disease, according to topline results released by Johnson & Johnson.

The Oklahoma Medical Research Foundation has received a $5.8 million award from the NIH for research into the diagnosis and management of Sjögren’s disease, according to a press release.

In 2023, Healio had questions, the experts had answers.